|
End-of-day quote
Nasdaq
2024-02-05
|
5-day change | 1st Jan Change | ||
| 0.3222 USD | -2.36% |
|
+2.32% | -20.05% |
Sales 2025 by Business Segment
Sales 2025 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Pharmaceuticals | - | - | 7.77M | 10.09M | 13.11M | |||||
Total Assets | 241M | 226M | 154M | 163M | 277M | |||||
Interest Expense | - | - | - | - | -89K | |||||
CAPEX | -35.31M | -48.15M | -7.9M | -120K | -3.37M | |||||
EBT | -92.29M | -110M | -117M | -130M | -124M | |||||
D&A | 50K | 1.25M | 4.29M | 3.42M | 1.92M | |||||
Operating Income | -92.31M | -112M | -118M | -137M | -126M | |||||
Net Income | -92.29M | -110M | -117M | -130M | -124M |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | - | - | 7.77M | 10.09M | 13.11M | |||||
Total Assets | 241M | 226M | 154M | 163M | 277M | |||||
Interest Expense | - | - | - | - | -89K | |||||
D&A | 50K | 1.25M | 4.29M | 3.42M | 1.92M | |||||
CAPEX | -35.31M | -48.15M | -7.9M | -120K | -3.37M | |||||
Net Income | -92.29M | -110M | -117M | -130M | -124M | |||||
EBT | -92.29M | -110M | -117M | -130M | -124M | |||||
Operating Income | -92.31M | -112M | -118M | -137M | -126M |
- Stock Market
- Stocks
- TNXP Stock
- TNXP Stock
- Financials Tonix Pharmaceuticals
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
